LRI Investments LLC Invests $441,000 in Intuitive Surgical, Inc. (NASDAQ:ISRG)

LRI Investments LLC bought a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 1,158 shares of the medical equipment provider’s stock, valued at approximately $441,000.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Intuitive Surgical by 1.6% in the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after buying an additional 493,126 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Intuitive Surgical by 1.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock valued at $5,726,102,000 after buying an additional 272,741 shares in the last quarter. Capital World Investors boosted its stake in Intuitive Surgical by 1.0% in the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock valued at $2,907,079,000 after buying an additional 73,634 shares in the last quarter. Edgewood Management LLC boosted its stake in Intuitive Surgical by 7.9% in the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after buying an additional 374,667 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its stake in Intuitive Surgical by 2.0% in the fourth quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock valued at $1,516,222,000 after buying an additional 88,977 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on ISRG. Jefferies Financial Group raised their price objective on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research note on Friday, April 19th. The Goldman Sachs Group assumed coverage on Intuitive Surgical in a research note on Thursday, May 30th. They set a “buy” rating and a $500.00 price target on the stock. Citigroup lifted their price target on Intuitive Surgical from $462.00 to $512.00 and gave the company a “buy” rating in a research note on Wednesday, July 10th. Stifel Nicolaus lifted their price target on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research note on Friday, July 19th. Finally, BTIG Research lifted their price target on Intuitive Surgical from $451.00 to $459.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $438.74.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of Intuitive Surgical stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $375.39, for a total value of $141,146.64. Following the completion of the sale, the executive vice president now directly owns 5,507 shares in the company, valued at $2,067,272.73. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of Intuitive Surgical stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $375.39, for a total value of $141,146.64. Following the completion of the sale, the executive vice president now directly owns 5,507 shares in the company, valued at $2,067,272.73. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Mark Brosius sold 175 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $389.16, for a total value of $68,103.00. Following the sale, the senior vice president now owns 883 shares of the company’s stock, valued at approximately $343,628.28. The disclosure for this sale can be found here. Over the last three months, insiders sold 13,358 shares of company stock worth $5,592,694. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Stock Performance

Shares of ISRG traded up $4.56 during mid-day trading on Friday, reaching $441.30. 1,196,597 shares of the company were exchanged, compared to its average volume of 1,795,967. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $468.78. The stock has a market capitalization of $156.82 billion, a PE ratio of 79.66, a PEG ratio of 4.81 and a beta of 1.39. The business has a 50 day simple moving average of $427.82 and a two-hundred day simple moving average of $398.55.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue was up 14.5% compared to the same quarter last year. During the same period last year, the company earned $1.18 earnings per share. On average, analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.